Beverly Wilshire Ltd (9QX) Fair Value & Analysis
Healthcare · SG · Market cap 10.7M SGD
Fair value as of: Jul 4, 2026
From 11 valuation models · updated today
Price vs Fair Value (12 months)
12‑month range 0.0080 SGD – 0.0140 SGD · the 0.0090 SGD price screens below the 0.0091 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Beverly Wilshire Ltd (9QX) currently trades at 0.0090 SGD, while our model-based Fair Value estimate is 0.0091 SGD — implying the stock looks roughly 1.0% undervalued today. We read business quality at 46/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Beverly Wilshire Ltd generated revenue of 8.7M SGD at a net margin of -2.9%. Revenue declined 35.5% year over year. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Beverly Wilshire Ltd., an investment holding company, engages in the trading and distribution, and medical businesses in Singapore and Malaysia. The company operates through three segments: Trading and Distribution; Aesthetic Medical and Healthcare; and Investment and Others. The Trading and Distribution segment engages in the trading and distribution of steel raw materials, consumables, instruments, and semi-finished products for steel mills, iron and steel foundries, and aluminum smelters in the Asia-Pacific region, as well as provision of ancillary services. The Aesthetic Medical segment offers aesthetic medical services, including the provision of aesthetic medical, beauty, and wellness services. The Investment and Others segment provides management services, as well as marketing, distribution, and related services. The company provides plastic surgery, cosmetic and reconstructive surgery, aesthetic dental care, cosmetological and aesthetical related treatments, hair …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beverly Wilshire Ltd reported revenue of 9.4M SGD in FY2025 versus 9.0M SGD in FY2021, a compound +1.2%/yr. Reported net income was 46.0K SGD in FY2025.
Is 9QX fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beverly Wilshire Ltd (9QX) undervalued?
What is the fair value of 9QX?
What is the quality score of 9QX?
What is the revenue of Beverly Wilshire Ltd (9QX)?
What is the net profit margin of 9QX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.